RedHill's trial of CR Zofran competitor could lead to US NDA
This article was originally published in Scrip
Executive Summary
Emerging Israeli biopharmaceutical company, RedHill Biopharma, has begun an "advanced" clinical trial with RHB-102, a once-daily controlled release formulation of the antiemetic, ondansetron, for the prevention of nausea and vomiting in cancer patients.